Lack of support for bexarotene as a treatment for Alzheimer's disease

Neuropharmacology

Volumn 100, Issue , 2016, Pages 124-130

  O'Hare, Eugene ^a   Jeggo, Ross ^b   Kim, Eun Mee ^c   Barbour, Bridgeen ^a   Walczak, Jean Sebastien ^d   Palmer, Philip ^a   Lyons, Taylor ^a   Page, Deaglan ^a   Hanna, Donncha ^a   Meara, Jolyon R ^e   Spanswick, David ^b,d,f   Guo, Jian Ping ^g   McGeer, Edith G ^g   McGeer, Patrick L ^g   Hobson, Peter ^e  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b NEUROSOLUTIONS LTD   (United Kingdom)

^c UNIVERSITY OF ULSTER   (United Kingdom)

^d Cerebrasol Limited   (Canada)

^e CARDIFF UNIVERSITY   (United Kingdom)

^f MONASH UNIVERSITY   (Australia)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Alzheimer's disease; Behavior; Beta amyloid; Bexarotene; Oligomers; Synaptic transmission

Indexed keywords

AMYLOID BETA PROTEIN; BEXAROTENE; CONDITIONED MEDIUM; TETRALIN DERIVATIVE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR DISORDER; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFICACY; DRUG TREATMENT FAILURE; EXCITATORY POSTSYNAPTIC POTENTIAL; FEMALE; LONG TERM POTENTIATION; MALE; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; RAT; RAT MODEL; ANIMAL; CHEMICALLY INDUCED; CHO CELL LINE; CONDITIONED MEDIUM; CRICETULUS; DISEASE MODEL; DRUG EFFECTS; HIPPOCAMPAL CA1 REGION; INSTRUMENTAL CONDITIONING; MAZE TEST; METABOLISM; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CA1 REGION, HIPPOCAMPAL; CHO CELLS; CONDITIONING, OPERANT; CRICETULUS; CULTURE MEDIA, CONDITIONED; DISEASE MODELS, ANIMAL; EXCITATORY POSTSYNAPTIC POTENTIALS; LONG-TERM POTENTIATION; MALE; MAZE LEARNING; MICE; MICE, TRANSGENIC; RATS; RATS, SPRAGUE-DAWLEY; TETRAHYDRONAPHTHALENES;

EID: 84942366578     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2015.04.020     Document Type: Article

References (27)

1. T.V. Bliss, and G.L. Collingridge A synaptic model of memory: long-term potentiation in the hippocampus Nature 361 6407 1993 31 39
2. M.A. Cenci, I.Q. Wishaw, and T. Schallert Animal models of neurological deficits: how relevant is the rat? Nat. Rev. Neurosci. 3 7 2002 574 579
3. J.P. Cleary, D.M. Walsh, J.J. Hofmeister, G.M. Shankar, M.A. Kuskowski, D.J. Selkoe, and K.H. Ashe Natural oligomers of the beta-amyloid protein specifically disrupt cognitive function Nat. Neurosci. 8 1 2005 79 84
4. P.E. Cramer, J.R. Cirrito, D.W. Wesson, C.Y. Lee, J.C. Karlo, A.E. Zinn, B.T. Casali, J.L. Restivo, W.D. Goebel, M.J. James, K.R. Brunden, D.A. Wilson, and G.E. Landreth ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models Science 335 6075 2013 1503 1506
5. C.B. Ferster, and B.F. Skinner Schedules of Reinforcement 1957 Prentice Hall New Jersey
6. N.F. Fitz, A.A. Cronican, I. Lefterov, and R. Koldamova Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models" Science 340 6135 2013 924-c
7. J.-P. Guo, S. Yu, and P.L. McGeer Simple in vitro assays to identify β-amyloid aggregation blockers for Alzheimer's disease therapy J. Alzheimer's Dis. 19 4 2010 1359 1370
8. A.K. Johnson, and A.N. Epstein The cerebral ventricles as the avenue for the dipsogenic action of intracranial angiotensin Brain Res. 86 3 1974 399 418
9. K.D. LaClair, K.F. Manaye, D.L. Lee, J.S. Allard, A.V. Savonenko, J.C. Troncoso, and P.C. Wong Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice Mol. Neurodegener. 8 2013 18
10. G.E. Landreth, P.E. Cramer, M.M. Lakner, J.R. Cirrito, D.W. Wesson, K.R. Brunden, and D.A. Wilson Response to comments on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models" Science 340 6135 2013 924-g
11. J. Lowednthal, S.C. Hull, and S.D. Pearson The ethics of early evidence - preparing for a possible breakthrough in Alzheimer's disease N. Eng. J. Med. 367 6 2012 488 490
12. E. O'Hare, D.I.C. Scopes, E.-M. Kim, P. Palmer, M. Jones, A.D. Whyment, D. Spanswick, H. Amijee, E. Nerou, B. McMahon, J.M. Treherne, and R. Jeggo Orally bioavailable small molecule drug protects memory in Alzheimer's disease models Neurobiol. Aging 34 4 2013 1115 1125
13. G. Paxinos, and C. Watson The Rat Brain in Stereotaxic Coordinates fourth ed. 1998 Academic Press New York
14. M.B. Podlisny, B.L. Ostaszewski, S.L. Squazzo, E.H. Koo, R.E. Rydell, D.B. Teplow, and D.J. Selkoe Aggregation of secreted amyloid beta protein into sodium dodecyl sulphate-stable oligomers in cell culture J. Biol. Chem. 270 16 1995 9564 9570
15. M.B. Podlisny, D.M. Walsh, P. Amorante, B.L. Ostaszewski, E.R. Stimson, J.E. Maggio, D.B. Teplow, and D.J. Selkoe Oligomerization of endogenous and synthetic amyloid beta protein at nanomolar levels in cell culture and stabilization of monomer by Congo red Biochemistry 37 11 1998 3602 3611
16. A. Poling, K.P. Morgan-Paisley, J.J. Panos, E.-M. Kim, E. O'Hare, J.P. Cleary, S. Lesne, K.H. Ashe, M. Porritt, and L. Baker Oligomers of the amyloid beta protein disrupt working memory: confirmation with two behavioural procedures Behav. Brain Res. 193 2 2008 230 234
17. A.R. Price, G. Xu, Z.B. Siemienski, L.A. Smithson, D.R. Borchelt, T.E. Golde, and K.M. Felsenstein Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models" Science 340 6135 2013 924-d
18. M.N. Reed, J.J. Hofmeister, L. Jungbauer, A.T. Welzel, C. Yu, M.A. Sherman, S. Lesne, M.J. LaDu, D.M. Walsh, K.H. Ashe, and J.P. Cleary Cognitive effects of cell-derived and synthetically derived Aβ oligomers Neurobiol. Aging 32 10 2011 1784 1794
19. G.M. Shankar, A.T. Welzel, J.M. McDonald, D.J. Selkoe, and D.M. Walsh Isolation of low-n amyloid β-protein oligomers from cultured cells, CSF, and brain Methods Mol. Biol. 670 2011 33 44
20. B.F. Skinner Operant behavior Am. Psychol. 18 8 1963 503 515
21. I. Tesseur, A.C. Lo, A. Roberfroid, S. Dietvorst, B. Van Broeck, M. Borgers, H. Gijsen, D. Moechars, M. Mercken, J. Kemp, R. D'Hooge, and B. De Strooper Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models" Science 340 6135 2013 924-e
22. M. Townsend, J.P. Cleary, T. Mehta, J.J. Hofmeister, S. Lesne, E. O'Hare, D.M. Walsh, and D.J. Selkoe Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers Ann. Neurol. 60 6 2006 668 676
23. L. Traykov, S. Baudic, N. Raoux, F. Latour, D. Rieu, A. Smagghe, and A.S. Rigaud Patterns of memory impairment and perseverative behaviour discriminate early Alzheimer's disease from subcortical vascular dementia J. Neurol. Sci. 229 2005 75 79
24. K. Veeraraghavalu, C. Zhang, S. Miller, J.K. Hefendehl, T.W. Rajapaksha, J. Ulrich, M. Jucker, D.M. Holzman, R.E. Tanzi, R. Vassar, and S.S. Sisodia Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models" Science 340 6135 2013 924-f
25. D.M. Walsh, I. Klyubin, J.V. Fadeeva, W.K. Cullen, R. Anwyl, and M.S. Wolfe Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo Nature 416 6880 2002 535 539
26. D.M. Walsh, I. Klyubin, G.M. Shankar, M. Townsend, J.V. Fadeeva, V. Betts, M.B. Podlisny, J.P. Cleary, K.H. Ashe, M.J. Rowan, and D.J. Selkoe The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention Biochem. Soc. Trans. 33 5 2005 1087 1090
27. T. Wells, and D.A. Carter Genetic engineering of neuronal function in transgenic rodents: towards a comprehensive strategy? J. Neurosci. Methods 108 2 2001 111 130